Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 1284-1293, 2006. First published May 11, 2006; 10.1373/clinchem.2006.067595
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.067595v1
52/7/1284    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kofoed, K.
Right arrow Articles by Eugen-Olsen, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kofoed, K.
Right arrow Articles by Eugen-Olsen, J.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Proteomics and Protein Markers
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 2006;52:1284-1293.)
© 2006 American Association for Clinical Chemistry, Inc.

Molecular Diagnostics and Genetics

Development and Validation of a Multiplex Add-On Assay for Sepsis Biomarkers Using xMAP Technology

Kristian Kofoed1,2,a, Uffe Vest Schneider1, Troels Scheel1, Ove Andersen1,2 and Jesper Eugen-Olsen1

1 Clinical Research Unit and2 Department of Infectious Diseases, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark.

aAddress correspondence to this author at: Clinical Research Unit 136, H:S Hvidovre Hospital, Kettegaard Allé 30, DK-2650 Hvidovre, Denmark. Fax 45-3632-3797; e-mail kristian.kofoed{at}hh.hosp.dk.

Background: Sepsis is a common and often fatal disease. Because sepsis can be caused by many different organisms, biomarkers that can aid in diagnosing sepsis and monitoring treatment efficacy are highly warranted. New sepsis markers may provide additional information to complement the currently used markers.

Methods: We used a combination of in-house and commercially available multiplex immunoassays based on Luminex® xMAP technology to assay biomarkers of potential interest in EDTA-plasma samples.

Results: A 3-plex assay for soluble urokinase plasminogen activator receptor (suPAR), soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), and macrophage migration inhibiting factor (MIF) was developed and validated in-house. This 3-plex assay was added to a commercially available interleukin-1ß (IL-1ß), IL-6, IL-8, granulocyte/macrophage colony-stimulating factor, and tumor necrosis factor-{alpha} human cytokine panel. No cross-reactivity was observed when the assays were combined. Correlation between values obtained with the 8-plex, the 5-cytokine panel, the 3 in-house 1-plex assays, and a suPAR ELISA ranged from 0.86 to 0.99. Mean within- and between-run CVs were 8.0% and 11%, respectively. Recoveries of suPAR, sTREM-1, and MIF calibrators were 108%, 88%, and 51%, respectively. In plasma collected from 10 patients with bacterial sepsis confirmed by blood culture, the assay detected significantly increased concentrations of all 8 analytes compared with healthy controls.

Conclusions: A commercially available xMAP panel can be expanded with markers of interest. The combined multiplex assay can measure the 8 analytes with high reproducibility. The xMAP technology is an appealing tool for assaying conventional cytokines in combination with new markers.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.